Takeda Pharmaceutical Co. Ltd. (TAK) Phase 3 PANTHER (Pevonedistat-3001) Trial Did Not Achieve Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Takeda Pharmaceutical Co. Ltd. (TAK) Phase 3 PANTHER (Pevonedistat-3001) Trial Did Not Achieve Primary Endpoint

Pre-Open Stock Movers 09/01: (ABVC) (PLAN) (BLCM) Higher; (LCID) (NIO) (ASND) Lower (more...)

September 1, 2021 9:22 AM EDT

Pre-Open Stock Movers:

ABVC BioPharma, Inc. (NASDAQ: ABVC) 45% HIGHER; filed new PCT (Patent Cooperation Treaty) applications in connection with its medicines that treat major depressive disorder (MDD) and Attention-Deficit Hyperactivity Disorder (ADHD). The two PCT applications describe the treatment methods of oral administrating compositions containing Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421). PDC-1421 is the active ingredient for both the companys MDD and ADHD drugs.

Lucid Group (NASDAQ: LCID) 21.8% LOWER; lock-up expires.

Anaplan, Inc. (NYSE:... More

Takeda (TAK) and Moderna (MRNA) Say No Evidence Found that Two Deaths in Japan Were Vaccine-Related

September 1, 2021 8:53 AM EDT

Moderna (NASDAQ: MRNA) and Takeda Pharmaceutical (NYSE: TAK) issued a joint statement today to say there is no evidence that the two deaths in Japan were related to the administration of the vaccine.

Two companies conducted a review that showed the rare presence of stainless steel particles... More